FDA is considering changes to the approval process for NSAID and proton pump inhibitor combination products that may result in the agency prohibiting the use of endoscopic gastric ulcer reduction to support a gastroprotective marketing claim.
That decision would raise the approval bar for a category of drugs that has recently become popular with certain companies: combining the pain properties of a non-steroidal anti-inflammatory drug with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?